Compare

Azelis Group NV/€AZE

1D1W1M3M6MYTD1Y5YMAX

About Azelis Group NV

Azelis Group NV operates within the specialty chemicals and food ingredients industry, focusing on the distribution of innovative chemical and food ingredients. The company serves various sectors, including personal care, food and health, animal nutrition, home care, and industrial applications. Established in 2001, Azelis is headquartered in Antwerp, Belgium, and has developed a strong global presence with operations in over 50 countries. Its strategic positioning benefits from a network of laboratories and technical centers, enabling tailored solutions and value-added services for customers. Azelis’s competitive strength lies in its ability to leverage deep local market insights while maintaining close relationships with key suppliers.
Ticker
€AZE
Sector
Industrials
Primary listing
BSE
Employees
4,000
Headquarters
Antwerp, Belgium
Website
www.azelis.com

Azelis Group NV Metrics

BasicAdvanced
€2.8B
25.01
€0.46
0.54
€0.16
1.37%

What the Analysts think about Azelis Group NV

Analyst ratings (Buy, Hold, Sell) for Azelis Group NV stock.
Analyst projections of the future price of Azelis Group NV stock.

Bulls say / Bears say

The recovery accelerated: Q3 revenue grew 8.5% at constant currency, including 8.2% organic growth, with all regions contributing positive organic growth. Management is targeting positive organic adjusted EBITA growth for 2026. (Azelis)
Profit is growing faster than sales: organic adjusted EBITA rose 14.3% in Q3 and the margin expanded by 54 basis points to 10.2%. This points to better operating leverage, supported by pricing and cost discipline. (Azelis)
Azelis has set medium-term targets for mid-to-high single-digit annual gross profit growth, high-single-digit adjusted EBITA growth and a doubling of EPS by 2031. Delivering these goals would support sustained earnings growth. (Azelis)
Azelis recorded a €350m goodwill impairment on Americas acquisitions completed in 2021–23, reflecting lower valuations. It highlights the risk that past deals may not deliver the value paid for them. (Azelis, Reuters)
Nine-month free cash flow fell 35.2% to €190m as working capital absorbed cash, while net debt was €1.6bn and leverage 3.46 times. This leaves limited headroom if cash generation disappoints or trading weakens again. (Azelis)
The recovery remains uneven: EMEA Life Sciences revenue fell 3.1% organically in Q3, and Azelis says volatility remains elevated. Persistent weakness in that business could weigh on group growth even as industrial chemicals rebound. (Azelis)
Data summarised monthly by Lightyear AI. Last updated on 22 Oct 2026.

Azelis Group NV Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

Azelis Group NV Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

Funds containing Azelis Group NV

AllUSDEURGBP
Funds
Fund name
Fund size
€AZE weighting
Xtrackers MSCI Europe Small Cap€DX2J
$3.6B0.21%
Xtrackers MSCI Europe Small Cap£XXSC
$3.6B0.21%
iShares MSCI World Small Cap£WLDS
$9B0.03%
iShares MSCI World Small Cap€IUSN
$9B0.03%
iShares MSCI World Small Cap$WSML
$9B0.03%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.